Tenascin-C: exploitation and collateral damage in cancer management.
Fiche publication
Date publication
janvier 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NOEL Georges, Dr OREND Gertraud
Tous les auteurs :
Spenle C, Saupe F, Midwood K, Burkel H, Noel G, Orend G
Lien Pubmed
Résumé
Abstract Despite an increasing knowledge about the causes of cancer, this disease is difficult to cure and still causes far too high a death rate. Based on advances in our understanding of disease pathogenesis, novel treatment concepts, including targeting the tumor microenvironment, have been developed and are being combined with established treatment regimens such as surgical removal and radiotherapy. Yet it is obvious that we need additional strategies to prevent tumor relapse and metastasis. Given its exceptional high expression in most cancers with low abundance in normal tissues, tenascin-C appears an ideal candidate for tumor treatment. Here, we will summarize the current applications of targeting tenascin-C as a treatment for different tumors, and highlight the potential of this therapeutic approach.
Référence
Cell Adh Migr. 2015 Jan 8:0.